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Abstract : Triple-negative breast cancer (TNBC) is a heterogenous disease. For personalized medicine, it is essen-
tial to identify and classify tumor subtypes to develop effective therapeutic strategies. Although gene expression 
profiling has identified several TNBC subtypes, classification of these tumors remains complex. Most TNBCs ex-
hibit an aggressive phenotype, but some rare types have a favorable clinical course. In this review, we summarize 
the classification and characteristics related to the various TNBC subtypes, including the rare types. Therapeu-
tic methods that are suitable for each subtype are also discussed. Of the intrinsic breast cancer subtypes identi-
fied by gene expression analysis, the basal-like subtype specifically displayed decreased expression of an estro-
gen receptor (ER) and human epidermal growth factor receptor 2 (HER2) cluster. We also present results that 
characterize the TNBC and basal-like phenotypes. TNBC may be categorized into four major classes : basal-like, 
immune-enriched, mesenchymal, and luminal androgen receptor. Therapeutic strategies for each subtype have 
been proposed along with newly approved targeted therapies for TNBC, such as immune checkpoint inhibitors. 
Understanding the classification of TNBC based on gene expression profiling in association with clinicopatho-
logical factors will facilitate accurate pathological diagnosis and effective treatment selection. J. Med. Invest. 68 
: 213-219, August, 2021
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INTRODUCTION
 
The biological indicators of breast cancer include tumor in-
vasion diameter, number of metastatic lymph nodes, disease 
stage, histological grade, nuclear grade, histological type, and 
lymphatic / vascular invasion (1, 2). The estrogen receptor (ER), 
progesterone receptor (PgR), human epidermal growth factor re-
ceptor 2 (HER2), and Ki-67 have been evaluated in pathological 
specimens using immunohistochemistry (IHC) and fluorescence 
in situ hybridization. Significant attention has been focused on 
the classification of breast cancer based on gene expression 
profiling ; however, IHC has the advantage of cost and time 
compared with microarray analysis and can also reveal local 
expression including in situ lesions and invasive lesions. For rou-
tine clinical practice, the immunohistochemical classification of 
breast cancer is used as a surrogate for subtype and a guide for 
treatment selection (3, 4).
Triple-negative breast cancer (TNBC) is devoid of hormone 
receptor (ER and PgR) expression, as well as overexpression or 
amplification of HER2. Both hormone and anti-HER2 therapies 
are ineffective for TNBC ; therefore, chemotherapy is required. 
TNBC represents a variety of tumors, and ongoing research is 
aimed at developing targeted treatments based on its biological 
characteristics (5). Cancer genomic panels using formalin-fixed, 
paraffin-embedded tumor blocks have enabled the examination 
of many important genes and biomarkers that may indicate if a 
targeted therapy or a clinical trial is warranted for a patient (6).
TNBCs can be subtyped by various molecular classification 
schemes. The basal-like subtype is a type of invasive breast 
cancer originally defined by gene expression profiling studies. 
Protein expression patterns characteristic of the basal-like 
subtype include high expression of basal keratins and epidermal 
growth factor receptor (EGFR) (7). The basal-like subtype exhib-
its pathological features including high histological grade, high 
proliferative rate, and prominent lymphocyte infiltration (8, 9) 
and is enriched in patients harboring tumor suppressor protein 
53 (TP53) and BRCA1 mutations (10, 11). Most basal-like subtype 
breast cancers exhibit poor prognosis (12). However, some rare 
TNBC types have exceptionally good prognosis. Basal-like 
subtype breast cancer and TNBC share common biological and 
pathological features with a 70%–80% overlap (13). 
This review focuses on the classification of TNBC subtypes 
compared with the histology of the basal-like subtype and other 
rare subtypes. We also discuss targeted therapies that are avail-
able for each TNBC subtype and introduce some of our study 
results, including characteristics of TNBC and the basal-like 
phenotype. 
TNBC SUBTYPING
Gene expression profiles and classification of the intrinsic TNBC 
subtypes
Breast cancer is a heterogenous group of diseases that can 
be categorized using gene expression profiling into luminal A, 
luminal B, HER2-enriched, basal-like, and normal-like sub-
types (14). These so-called intrinsic subtypes show differences in 
incidence, age at diagnosis, prognosis, and response to treatment 
(14, 15). Lehmann et al. identified six TNBC subtypes using the 
gene expression profiling results of 21 breast cancer datasets. 
These included the basal-like subtype, which was divided into 
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BL1 and BL2, and four other subtypes : immunomodulatory 
(IM), mesenchymal (M), mesenchymal stem-like (MSL), and 
luminal androgen receptor (LAR). For BL1, pathways associ-
ated with cell division and DNA damage repair (ATR / BRCA) 
were enriched, and Ki-67 expression was high, suggesting active 
cell proliferation. For BL2, growth factor signaling (EGF, NGF, 
MET, Wnt / β-catenin, and IGF1R pathways), glycolysis, and 
gluconeogenesis-related genes were upregulated. Growth factor 
receptors and myoepithelial markers (TP63, CD10) were also 
highly expressed (16). A histopathological examination and gene 
expression analysis of laser-capture microdissection specimens 
revealed that the IM type contained infiltrating lymphocytes 
and the MSL type contained many stromal cells in the tumor 
tissue. The classification was organized into four subtypes : BL1, 
BL2, M, and LAR (TNBC type-4) (17). 
The claudin-low subtype was considered to be a new intrinsic 
subtype. This subtype was characterized by low or absent ex-
pression of luminal differentiation markers and tight junction 
proteins, as well as enrichment of epithelial-mesenchymal 
transition markers, immune response genes, and cancer stem 
cell-like features (18). Most claudin-low subtypes showed M and 
MSL subtypes as classified by Lehmann et al. (19). 
Burstein et al. classified TNBCs into four types using RNA 
and DNA profiling : basal-like immune-suppressed (BLIS), bas-
al-like immune-activated (BLIA), mesenchymal (MES), and lu-
minal / androgen receptor (LAR). The expression levels of genes 
controlling B cell, T cell, and natural killer cell functions were 
low in the BLIS subtype and high in the BLIA subtype. In the 
BLIS subtype, the expression of molecules involved in antigen 
presentation, immune cell differentiation, and signal communi-
cation between immune cells was low ; however, the expression 
of SOX family transcription factors was high. The BLIA subtype 
exhibited significant STAT transcription factor-mediated path-
way activation. Among the four subtypes, BLIA had the best 
prognosis, whereas BLIS had the worst (20).
The classification of TNBC is very complex and involves basal 
markers, stem-cell markers, mesenchymal traits, androgen re-
ceptor (AR) expression, and immune markers (21). 
TNBC and basal-like subtype, surrogate subtype classification by 
immunohistochemistry
High molecular weight cytokeratins, such as CK5 / 6, CK14, 
and CK17, are expressed in cells near the basement membrane 
in many epithelia and are known as basal keratins (22). IHC 
analysis of the basal keratins is used to define breast cancer 
exhibiting a basal phenotype as a surrogate of gene expression. 
Breast cancer with a basal phenotype is common in young 
people and is characterized by histologically prominent mitotic 
figures and nuclear atypia. It is also accompanied by extensive 
necrosis and marked lymphocyte infiltration (8, 9). The majority 
of breast cancers that occur in BRCA1 mutation carriers are of 
the basal-like subtype (11). Tumors arising in BRCA1 carriers 
have many similarities to sporadic basal-like tumors with BRCA1 
dysfunction, such as low expression of BRCA1 messenger RNA 
(23).
In our study, TNBC accounted for 15% of the 513 invasive 
cancers examined. Among the TNBCs, 61% were positive for 
CK5 / 6, CK14, or CK17 by IHC and exhibited a basal phenotype. 
Among the TNBCs, those exhibiting a basal phenotype had a 
larger tumor diameter, higher nuclear grade, and higher EGFR 
positivity compared with the non-basal phenotypes. In addition, 
breast cancer exhibiting a basal phenotype was not significantly 
different from the non-basal phenotype within TNBC, although 
there was a tendency for early recurrence (24). 
The basal-like subtype has much in common with TNBC 
histology and clinical behavior, but it is not exactly the same. 
It has been reported that 21% of TNBCs are not basal-like and 
31% of breast cancers showing basal-like gene expression are not 
triple-negative (13).
There is currently no consensus on the optimal immunohis-
tochemical panel to define the basal-like subtype. At the 2017 
St. Gallen Consensus Conference, it was determined that the 
basal-like subtype should be defined by gene expression profiling 
assay only (4) (Figure 1). In the latest WHO classification of 
breast cancer, the basal-like subtype was recognized as one of 
the intrinsic breast cancer subtypes based on genetic analysis 
like a quantitative RT-PCR-based test with a curated list of 50 
genes (the PAM50 gene signature) (25). According to the WHO 
classification, breast cancers showing basal-like features are 
described as carcinomas showing a medullary pattern, which 
is one of the special morphological patterns of invasive breast 
carcinoma of no special type (26). 
HISTOLOGICAL TYPES OF TNBC
Most TNBCs are poorly differentiated, highly malignant inva-
sive ductal carcinomas (8, 9). However, TNBC is a heterogeneous 
disease and includes special morphological patterns and rare 
types that include carcinoma with medullary pattern, apocrine 
carcinoma, adenoid cystic carcinoma (ACC), secretory carcino-
ma, and metaplastic carcinoma (Figure 2A-H). 
Carcinoma with medullary pattern is often associated with 
significant lymphocyte infiltration and has a good prognosis 
despite its high-grade histology (27). Carcinoma with medullary 
pattern is correlated with the intrinsic IM subtype as classified 
by Lehmann et al. (16) and a subgroup of the basal-like subtype 
(28). 
Carcinoma with apocrine differentiation is characterized by 
increased androgen signaling and often overlaps with the HER2 
group based on their gene expression profiles (29).
ACC is a salivary gland-type breast cancer that is generally 
low-grade and shows an indolent clinical behavior (30). Approxi-
mately half of ACCs are found in the subareolar area. The pres-
ence of a MYB-NFIB fusion gene resulting from a specific t(6 ; 9) 
chromosomal translocation was found in ACC (31).
Secretory carcinoma is associated with a t(12 ; 15) transloca-
tion, which results in an ETV6-NTRK3 fusion gene (32). Most se-
cretory carcinomas exhibit low to moderate grade histology with 
Figure 1.　Surrogate subtypes with immunohistochemistry and 
intrinsic subtypes of breast cancer. Modified from Fig.2.88 in WHO 
classification of tumours, 5th edition, breast tumours.
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a favorable clinical course (33). Inhibitors that target NTRK3 
have recently been developed and show efficacy in patients with 
secretory breast carcinoma (34).
Metaplastic carcinomas are a heterogeneous group of tumors 
characterized by metaplastic differentiation of the neoplastic 
epithelium to squamous and / or mesenchymal cells. Metaplastic 
carcinomas show genetic similarities with the MSL subtype 
in Lehmann’s classification and the claudin-low subtype (35). 
In general, metaplastic carcinoma exhibits a low survival rate 
and resistance to chemotherapy (36), but some cases of fibroma-
tosis-like metaplastic carcinoma have been associated with a 
favorable clinical outcome (37). 
 Each rare TNBC type has characteristic pathological findings 
and a distinct clinical course. Therefore, optimal treatment for 
these tumors requires an accurate pathological diagnosis.
CLASSIFICATION OF TNBC AND TARGETED THERAPY
TNBC is being refined based on its molecular characteristics 
and clinical response to targeted therapies. These molecular 
subtypes show distinctive clinical behaviors, including treat-
ment responses (Table 1). According to Lehmann et al., there is 
overlap between immune-enriched subtypes and other subtypes. 
Regardless of tumor subtype, the IM component for each tumor 
was highly correlated with percentage of tumor-infiltrating 
lymphocytes. The IM subtype likely reflects the presence of gene 
expression contributed by immune infiltrates with the carcino-
ma cells having the signature of a different subtype. BL1, BL2, 
MSL, and LAR-classified tumors had representatives with high 
correlations with the IM subtype. In contrast, M-classified tu-
mors had a very low correlation with the IM group (17) (Figure 3). 
Basal-like subtype
For the basal-like subtype, cell cycle and DNA damage re-
sponse pathways are significantly activated, which results in 
increased cell proliferation. Therefore, targeting the DNA dam-
age response pathways is a rational therapeutic approach. This 
subtype is highly sensitive to platinum drugs and poly (ADP-ri-
bose) polymerase (PARP) inhibitors (38, 39). BRCA1 and BRCA2 
function as tumor suppressor genes and play major roles in the 
DNA repair systems, specifically in repairing double-stranded 
breaks by homologous recombination. When homologous recom-
bination is dysfunctional (homologous recombination deficiency, 
HRD), which is commonly observed in cases with BRCA1 / 2 muta-
tions, double-stranded breaks result in genomic instability (40). 
PARP1 binds to single-stranded breaks during the DNA repair 
process. PARP inhibitors can trap PARP1 and induce cell death 
by preventing this single-stranded break repair. Double-strand-
ed breaks occur in patients with BRCA mutations that lack a 
functional homologous recombination pathway (41). 
Masuda et al. have reported a retrospective analysis of TNBC 
Figure 2.　Representative histological appearance of rare triple-negative breast cancer (TNBC). (A) Carcinoma with 
medullary pattern. Carcinoma cells show high histological grade and syncytial architecture with no glandular structures. (B, 
C) Carcinoma with apocrine differentiation. Carcinoma cells exhibit abundant, granular eosinophilic cytoplasm and enlarged 
nuclei with prominent nucleoli (B). Immunohistochemistry for androgen receptor showing strong positive staining (C). (D) 
Adenoid cystic carcinoma. Neoplastic cells are arranged in tubular and cribriform patterns. The pseudolumina are filled with 
stromal matrix including basement membrane. (E) Secretory carcinoma. The tumor cells are arranged in a microcystic growth 
pattern with extracellular secretion, simulating thyroid follicles. (F) Fibromatosis-like metaplastic carcinoma. Spindle cells with 
low-grade or no atypia are arranged in wavy fascicles. (G) Matrix-producing carcinoma. The discohesive cells are contained in a 
chondroid matrix. (H) Metaplastic carcinoma, squamous type shows carcinoma cells with abundant eosinophilic cytoplasm and 
focal keratinization. Scale bars, 100 µm.
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subtype based on response rates to neoadjuvant chemotherapy. 
The BL1 subtype achieved the highest pathological complete 
response rate (52%), while the BL2 subtype was found to have 
the lowest response rate (0%) (42). Standard chemotherapeutics, 
palatinum salts, and PARP inhibitors may be the most effective 
options currently available for patients with the BL1 subtype. 
BL2 has unique gene ontologies involving growth factor signal-
ing, such as the EGF, MET, and IGF1R pathways. BL2 subtype 
patients may be candidates for EGFR or IGF1R inhibitors.
Immune-enriched subtype 
This subtype includes tumors enriched for genes associated 
with immune cell processes. This phenotype is common in the 
IM subtype as classified by Lehmann et al. (16) and the BLIA 
subtype as classified by Burstein et al. (20). Immunotherapies, in-
cluding immune checkpoint inhibitors, have attracted attention 
for TNBC treatment.
Programmed death-1 (PD-1) is a T-cell inhibitory receptor that 
regulates the immune system by downregulating the T-cell re-
sponse upon binding with its ligand, PD-L1, which is expressed 
in cancer cells. While activation of this pathway protects cancer 
cells from immune cell-mediated death, inhibition of PD-1 or 
PD-L1 can restore the antitumor effects of T-cells. In patients 
with TNBC, PD-L1 is expressed on tumor-infiltrating immune 
cells as well as on tumor cells. When at least 1% or more of 
immune cells are immunohistochemically positive for PD-L1 
in tumor tissue and at the tumor margin, targeted therapy 
with anti-PD-L1 monoclonal antibodies may be considered (43) 
(Figure 4).
Mesenchymal subtype
The mesenchymal and mesenchymal stem-like subtypes are 
characterized by gene clusters associated with cell motility, 
matrix interactions, growth factors, and epithelial-mesenchy-
mal transition. Lehmann et al. proposed that cell models for 
mesenchymal and mesenchymal stem-like TNBC may be sen-
sitive to mTOR inhibitors because these cells exhibit activated 
PI3K / AKT / mTOR signaling resulting from the mutation of 
PIK3CA or deactivation of PTEN (16).
Luminal AR subtype
The AR belongs to the nuclear steroid hormone receptor family 
and regulates cell proliferation, apoptosis, and promotes cell mi-
gration and invasion in TNBCs (44). It is expressed in TNBCs, 
primarily in the LAR subtype, and is associated with apocrine 
histologic features (45). Barton et al. demonstrated that AR sup-
pression enhances sensitivity to chemotherapy by decreasing the 
resistant cancer stem cell-like population (46). Lehmann et al. 
Table 1.　Triple-negative breast cancer molecular subtype and potential targets for therapy.
Subtype Molecular Features Important Markers Therapeutic Targets / Drugs
BL1 Elevated cell cycle and DNA damage response gene expression
ATR/BRCA, Ki-67 Cisplatin, PARP inhibitors
BL2 Enriched in growth factor signaling, metabolic pathways, and myoepithelial marker expression
EGFR, IGF1R, NGF, MET, 
Wnt / b-catenin, EPHA2, TP63 Growth factor inhibitors
IM Genes involved in cytokine and immune signaling transduction pathways
IL-12, IL-7, NFKB, TNF, 
JAK / STAT
PD-1 / PD-L1 inhibitors, 
other immune 
checkpoint inhibitors
M Gene expression for EMT, cell motility, and differentiation
Wnt, ALK, TGF-β
PI3K / mTOR inhibitors, 
growth factor inhibitors, 
Src inhibitors
MSL
Increased growth factor signaling compared with (M),
low proliferation, enrichment of genes associated 
angiogenesis and stem cells, low claudin expression
EGFR, PDGF, ERK1/2, 
TGF-β , Wnt / β -catenin
PI3K / mTOR inhibitors, 
growth factor inhibitors, 
Src inhibitors
LAR Increased in hormonally regulated pathways, AR signaling, high rate of PIK3CA activating mutations
AR , FOXA1, KRT18, XBP1 AR antagonists, PI3K 
inhibitors, Hsp inhibitors
Modified from Lehmann et al. (16) ; ALK, anaplastic lymphoma kinase ; ATR, ataxia telangiectasia and Rad3- related protein ; EGFR, 
epidermal growth factor receptor ; EMT, epithelial-mesenchymal transition ; EPHA2, EPH receptor A2 ; ERK, mitogen-activated 
protein kinase ; FOXA1, forkhead box A1 : Hsp90, heat shock protein 90 ; IGF1R, insulin like growth factor 1 receptor ; IL, interleu-
kin ; JAK, Janus kinase ; MET, hepatocyte growth factor receptor ; mTOR, mechanistic target of rapamycin ; NF-kB, nuclear fac-
tor-kappa B ; NGF, nerve growth factor ; PARP, poly(ADP-ribose) polymerase ; PD-1, programmed cell death 1 ; PDGF, platelet-derived 
growth factor ; PD-L1, programmed cell death 1-ligand 1 ; PI3K, phosphoinositide 3-kinase ; PIK3CA, phosphatidylinositol-4,5-bis-
phosphate 3-kinase catalytic subunit alpha ; Src, SRC proto-oncogene ; STAT, signal transducer and activator of transcription ; TGFβ, 
transforming growth factor beta ; TNF, tumor necrosis factor ; Wnt, Wnt family member ; XBP1, X-box binding protein 1. 
Figure 3.　Classification of triple-negative breast cancer from 
genomic and transcriptomic data. BL1, basal-like 1 ; BL2, basal-
like 2 ; BLIA, basal-like immune-activated ; BLIS, basal-like 
immune-suppressed ; LAR, luminal androgen receptor ; IM, 
immunomodulatory ; MSL, mesenchymal stem-like ; M, 
mesenchymal ; TNBC, triple-negative breast cancer. Modified from 
Lehmann et al. (16, 17), Burstein et al. (20), and Fig.2.88 in WHO 
classification of tumours, 5th edition, breast tumours.
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showed that PIK3CA gene mutations frequently occur in AR-pos-
itive patients with TNBC. A synergistic effect was observed with 
the combination of AR antagonists and PI3K inhibitors in an 
AR-positive cell line and xenograft models (47). AR and PI3K 
inhibition have been proposed as therapeutic strategies (48).
CONCLUSION AND OUTLOOK
The advent of next-generation sequencing that can be used to 
analyze expression changes in many genes has paved the way 
for genomic medicine. Nucleic acids contained in formalin-fixed 
paraffin-embedded tissue blocks used for routine pathological 
diagnosis may also be used for genomic analysis. A sufficient 
amount of high-quality nucleic acids is available following the 
preparation and examination of paraffin blocks (49). Block selec-
tion, indicating the tumor areas on the slide glass for macrodis-
section, and determination of tumor content have also become 
important pathology tasks (50). It is important for clinicians 
and pathologists to share data and strive for high-quality patho-
logical and genomic diagnoses. The concept of breast cancer 
subtype classification is expected to change with advances and 
widespread use of molecular biological tests such as oncogene 
and multigene assays. Understanding and accepting the concept 
of new subtypes is important, but it is also important to closely 
observe the findings of histopathological specimens and provide 
accurate and detailed information.
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